Samsung Biologics Signs $262 Million Manufacturing Deal, Extending Commitments Through 2033

Samsung Biologics has signed a $262 million agreement to provide manufacturing services to a European pharma company from its site in Songdo, South Korea. The company did not disclose the customer or the product, citing client confidentiality, but said the manufacturing commitments extend through 2033.

That timing is the main signal in the announcement. Samsung Biologics is in the middle of a multiyear capacity buildout, and a contract that runs to 2033 suggests the company is still finding ways to lock in demand well ahead of delivery, even as investors question whether aggressive expansion could pressure utilization.

The commercial picture

Samsung Biologics CFO Seungho Ryu said last month that the four plants at the company’s Bio Campus I in Songdo are at full capacity. A fifth plant, the first at Bio Campus II, opened in April 2025 after a 1.9 trillion South Korean won ($1.4 billion) investment and is progressing through ramp-up as scheduled, according to Ryu.

The company plans to build another three plants at Bio Campus II by 2032. Once completed, Bio Campus II is expected to have 720 kL of manufacturing capacity, compared with 605 kL at the original site. Samsung Biologics currently has 785 kL of capacity across its five plants in Songdo, plus 60 kL at the Rockville, Maryland, site acquired from GSK this year.

Ryu has pushed back on concerns that expanding supply could weaken plant utilization. He said Samsung Biologics expects the market supply-demand utilization rate to increase from the mid-70% range in 2026 to the low-80% range in 2030, which he said indicates the market is expected to remain undersupplied.

The road here

Further expansion is already planned beyond the current Songdo buildout. Samsung Biologics has secured land for Bio Campus III, which it plans to develop from 2027 to 2034. To help fund that expansion and its takeover of PolyPeptide, the company recently announced a 3 trillion South Korean won ($2.2 billion) rights offering.

The PolyPeptide acquisition would add peptide production capacity and broaden Samsung Biologics into a segment benefiting from demand tied to GLP-1 drugs for diabetes and obesity. In the near term, the company is focused on completing that takeover and integrating the acquired sites, while Ryu said Samsung Biologics remains open to additional deals and is reviewing strategic investment opportunities tied to new modalities, overseas manufacturing sites and technologies.